Showing 5451-5460 of 5771 results for "".
- Eyevance Acquires Global Rights to Persistent Corneal Epithelial Defect Treatment Nexagonhttps://modernod.com/news/eyevance-acquires-global-rights-to-persistent-corneal-epithelial-defect-treatment-nexagon/2479822/Eyevance Pharmaceuticals announced a worldwide licensing agreement with OcuNexus Therapeutics for Nexagon, a 30-base antisense oligomer being developed for the orphan indication of persistent corneal epithelial defect (PED) nonresponsive to standard of care. Terms of the deal were not disc
- Visioneering Technologies Selects Corneal Lens Corporation NZ and Contact Lens Centre Australia to Distribute NaturalVue Brand Contact Lenses in ANZhttps://modernod.com/news/visioneering-technologies-selects-corneal-lens-corporation-nz-and-contact-lens-centre-australia-to-distribute-naturalvue-brand-contact-lenses-in-anz/2479825/Visioneering Technologies announced that it has signed an agreement with Corneal Lens Corporation (CLC) and its associated company Contact Lens Centre Australia (CLCA), making them authorized distributors of Visioneering’s NaturalVue (etafilcon A) Brand 1 Day Contact Lenses in New Zealand and Aus
- Eyenuk Expands into Germany with Launch of EyeArt Artificial Intelligence Eye Screening for Diabetic Retinopathyhttps://modernod.com/news/eyenuk-expands-into-germany-with-launch-of-eyeart-artificial-intelligence-eye-screening-for-diabetic-retinopathy/2479826/Eyenuk announced its expansion into Germany with the adoption of EyeArt artificial intelligence (AI) technology for the screening of diabetic retinopathy at Diabetes Center Mergentheim in Bad Mergentheim, Germany. The center is the first dedicated diabetic clinic in Germany to use artificial inte
- NovaBay Pharmaceuticals Names Jack McGovern Interim CEOhttps://modernod.com/news/novabay-pharmaceuticals-names-jack-mcgovern-interim-ceo/2479833/NovaBay Pharmaceuticals announced that Jack McGovern has been named interim Chief Executive Officer, expanding his responsibilities as Chief Financial Officer to include overseeing daily operations. Mark M. Sieczkarek, the company’s previous CEO, remains NovaBay’s Chairman and will focus on strat
- First FDA-Approved Iris Prosthesis Now Available in the United Stateshttps://modernod.com/news/veo-ophthalmics-launches-customflex-artificialiris-in-the-united-states/2479835/VEO Ophthalmics announced the launch of the ‘Customflex ArtificialIris,’ the first iris prosthesis available in the United States. The surgically implanted device received FDA approval on May 30, 2018 for use in children and adults for the treatment of iris defects resulting from cong
- Neuro-Optometric Rehabilitation Association Names New Members to its Advisory Boardhttps://modernod.com/news/nuero-optometric-rehabilitation-association-names-new-members-to-its-advisory-board/2479836/The Neuro-Optometric Rehabilitation Association, International (NORA) announced the addition of six new members to its Advisory Board, at the Association’s 27th Annual Conference in St. Louis. “Our new Advisory Board members bring a rich mix of backgrounds and experiences that w
- Nicox and Fera Pharmaceuticals to Focus on a Rare Disease Indication for Naproxcinodhttps://modernod.com/news/nicox-and-fera-pharmaceuticals-to-focus-on-a-rare-disease-indication-for-naproxcinod/2479837/Nicox SA and Fera Pharmaceuticals announced that they have amended their 2015 license agreement, which grante
- Novartis to File for New Lucentis (Ranibizumab) Indication in Retinopathy of Prematurity (ROP)https://modernod.com/news/novartis-to-file-for-new-lucentis-ranibizumab-indication-in-retinopathy-of-prematurity-rop/2479845/Novartis announced results from a phase 3 study of Lucentis (ranibizumab) versus laser surgery (the current standard of care) in premature infants with retinopathy of prematurity (ROP). Unlike laser surgery, which damages eye tissue and can be associated with significant complications such as hig
- Novartis: New Analysis of Phase 3 Brolucizumab Data Reinforces Superior Reduction of Retinal Fluidhttps://modernod.com/news/novartis-new-analysis-of-phase-3-brolucizumab-data-reinforces-superior-reduction-of-retinal-fluid/2479846/Novartis announced a new data analysis showing that retinal fluid was detected less often in patients treated with brolucizumab (RTH258) 6 mg versus aflibercept over four visits between weeks 36 to 48[1]. Retinal fluid is a key marker of disease activity in neovascular age-related macular degener
- Neurolens Appoints Davis Corley Chief Executive Officerhttps://modernod.com/news/neurolens-appoints-davis-corley-chief-executive-officer/2479848/Neurolens announced that its board of directors has named Davis Corley chief executive officer (CEO). Mr. Corley was a co-founder of neurolens in 2012 and has served as president since 2014, a role that he will continue. “Since day one, Davis has led the dev